Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
25% Off Benzinga's Most Powerful Trading Tools
Traders Win More with Benzinga's Exclusive News and Squawk
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Candel Therapeutics
(NASDAQ:CADL)
Intraday
$5.68
-0.14
[-2.41%]
After-Hours
$5.68
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$5.68
-0.14
[-2.41%]
At close: Apr 16
$5.68
0
[0.00%]
PreMarket: 8:50AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Candel Therapeutics Stock (NASDAQ:CADL)
Candel Therapeutics Stock (NASDAQ: CADL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 11, 2024
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
4 days ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
4 days ago
What's Going On With Candel Therapeutics Stock?
Erica Kollmann
-
4 days ago
Candel Therapeutics shares are trading higher after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.
Benzinga Newsdesk
-
4 days ago
Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For The Treatment Of Pancreatic Cancer
Benzinga Newsdesk
-
5 days ago
Tuesday, April 09, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
6 days ago
Friday, April 05, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Apr 5, 2024, 12:31PM
Candel Therapeutics Shares Resume Trading
Benzinga Newsdesk
-
Apr 5, 2024, 10:17AM
Candel Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 14.7%
Benzinga Newsdesk
-
Apr 5, 2024, 10:09AM
Candel Therapeutics Shares Resume Trade
Benzinga Newsdesk
-
Apr 5, 2024, 9:41AM
Candel Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -2.81%
Benzinga Newsdesk
-
Apr 5, 2024, 9:37AM
What's Going On With Candel Therapeutics Stock On Friday?
Vandana Singh
-
Apr 5, 2024, 9:22AM
CORRECTION: Candel Therapeutics Announced Interim Data From Randomized Phase 2 Clinical Trial Of CAN-2409 In Non-Metastatic Pancreatic Cancer.
Benzinga Newsdesk
-
Apr 5, 2024, 8:57AM
Candel Therapeutics shares are trading higher on continued strength after the company announced interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer.
Benzinga Newsdesk
-
Apr 5, 2024, 8:52AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Apr 5, 2024, 8:09AM
Thursday, April 04, 2024
Ford, Candel Therapeutics, Nvidia, Palantir, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Benzinga Neuro
-
Apr 4, 2024, 11:47PM
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Apr 4, 2024, 4:31PM
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
Avi Kapoor
-
Apr 4, 2024, 2:39PM
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Apr 4, 2024, 1:21PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Apr 4, 2024, 12:31PM
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
Avi Kapoor
-
Apr 4, 2024, 11:58AM
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
Vandana Singh
-
Apr 4, 2024, 10:24AM
Market-Moving News for April 4th
Benzinga Newsdesk
-
Apr 4, 2024, 8:33AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Apr 4, 2024, 8:09AM
Candel Therapeutics Announces Interim Data From Randomized Phase 2 Clinical Trial Of CAN-2409 In Non-Metastatic Pancreatic Cancer
Benzinga Newsdesk
-
Apr 4, 2024, 8:04AM
Monday, April 01, 2024
Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy
Vandana Singh
-
Apr 1, 2024, 12:49PM
Thursday, March 28, 2024
Candel Therapeutics Announces Oral Presentation During The 5th Glioblastoma Drug Development Summit With Update On Phase 1b Clinical Trial Of CAN-3110 In Recurrent High-Grade Glioma; Expects To Initiate Investigational New Drug-Enabling Work In A Second Indication Characterized By Nestin Expression
Benzinga Newsdesk
-
Mar 28, 2024, 4:17PM
Recap: Candel Therapeutics Q4 Earnings
Benzinga Insights
-
Mar 28, 2024, 9:40AM
Candel Therapeutics Reported Q4 EPS Loss of $(0.38) Vs $(0.16) Est, Cash Balance of $35.4M
Benzinga Newsdesk
-
Mar 28, 2024, 7:53AM
Tuesday, February 13, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Feb 13, 2024, 12:31PM
Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies
Jeremy Golden
-
Sponsored
Candel Therapeutics' CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
Benzinga Newsdesk
-
Feb 13, 2024, 7:31AM
Monday, February 05, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Feb 5, 2024, 8:06AM
Wednesday, December 13, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Dec 13, 2023, 4:31PM
Tuesday, December 12, 2023
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Dec 12, 2023, 1:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Dec 12, 2023, 12:31PM
US Stocks Edge Lower; Inflation Rate Slows to 3.1% In November
Avi Kapoor
-
Dec 12, 2023, 9:42AM
Candel Therapeutics shares are trading higher after the company announced it received FDA Fast Track Designation for CAN-2409 in pancreatic cancer.
Benzinga Newsdesk
-
Dec 12, 2023, 8:25AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Dec 12, 2023, 8:07AM
Candel Therapeutics Announced That The FDA Granted Fast Track Designation For Its Lead Investigational Adenovirus Asset CAN-2409 Plus Prodrug For The Treatment Of Patients With Pancreatic Ductal Adenocarcinoma
Benzinga Newsdesk
-
Dec 12, 2023, 8:02AM
Tuesday, November 28, 2023
Candel Therapeutics Shares Resumed Trade
Benzinga Newsdesk
-
Nov 28, 2023, 9:55AM
Candel Therapeutics Announces Restructuring To Prioritize Resources On Key Value Drivers For Expanded Development Of CAN-3110, The enLIGHTEN Discovery Platform, And Key Clinical Readouts For CAN-2409; Decreases Workforce By ~50%
Benzinga Newsdesk
-
Nov 28, 2023, 9:04AM
Candel Therapeutics Shares Halted, News Pending
Benzinga Newsdesk
-
Nov 28, 2023, 9:03AM
Monday, November 13, 2023
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk
-
Nov 13, 2023, 8:48AM
Thursday, November 09, 2023
Recap: Candel Therapeutics Q3 Earnings
Benzinga Insights
-
Nov 9, 2023, 8:50AM
Candel Therapeutics Q3 EPS $(0.29) Misses $(0.19) Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 8:15AM
Monday, November 06, 2023
Why Is Cancer Player Candel Therapeutics Stock Trading Higher Today?
Vandana Singh
-
Nov 6, 2023, 1:04PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Nov 6, 2023, 12:31PM
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance
Benzinga Newsdesk
-
Nov 6, 2023, 8:31AM
Friday, November 03, 2023
Candel Therapeutics Announces Initial Interim Data from Randomized Phase 2 Clinical Trial Of CAN-2409 In Non-Metastatic Pancreatic Cancer
Benzinga Newsdesk
-
Nov 3, 2023, 12:04PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch